The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oncology Adjuvants Market Research Report 2025
Synopsis
Oncology adjuvants are substances or therapies used in combination with primary cancer treatments, such as surgery, chemotherapy, or radiation therapy, to enhance their efficacy or reduce the risk of cancer recurrence.
The global Oncology Adjuvants market was valued at US$ 469.7 million in 2023 and is anticipated to reach US$ 599 million by 2030, witnessing a CAGR of 3.5% during the forecast period 2024-2030.
The market for oncology adjuvants is driven by the need for improved cancer treatment outcomes and the demand for personalized and targeted cancer therapies. The market's growth is also influenced by ongoing research in cancer immunotherapy and the development of novel adjuvant therapies.
This report aims to provide a comprehensive presentation of the global market for Oncology Adjuvants, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Adjuvants.
Report Scope
The Oncology Adjuvants market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Adjuvants market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Adjuvants manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Amgen
BMS
Biogen
Sanofi
AstraZeneca
Pfizer
Hengrui Medicine
Hisun Pharmaceutical
Yibai Pharmaceutical
SL Pharmaceutical
Zhendong Pharmaceutical
Main Luck Pharmaceuticals
Sanjiu Medical
Livzon Pharmaceutical
Segment by Type
Radiotherapy
Chemotherapy
Immunotherapy
Hormone therapy
Targeted therapy
Segment by Application
Cancer Research Institutes
Cancer Hospitals
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oncology Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oncology Adjuvants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Oncology adjuvants are substances or therapies used in combination with primary cancer treatments, such as surgery, chemotherapy, or radiation therapy, to enhance their efficacy or reduce the risk of cancer recurrence.
The global Oncology Adjuvants market was valued at US$ 469.7 million in 2023 and is anticipated to reach US$ 599 million by 2030, witnessing a CAGR of 3.5% during the forecast period 2024-2030.
The market for oncology adjuvants is driven by the need for improved cancer treatment outcomes and the demand for personalized and targeted cancer therapies. The market's growth is also influenced by ongoing research in cancer immunotherapy and the development of novel adjuvant therapies.
This report aims to provide a comprehensive presentation of the global market for Oncology Adjuvants, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Adjuvants.
Report Scope
The Oncology Adjuvants market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Adjuvants market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Adjuvants manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Amgen
BMS
Biogen
Sanofi
AstraZeneca
Pfizer
Hengrui Medicine
Hisun Pharmaceutical
Yibai Pharmaceutical
SL Pharmaceutical
Zhendong Pharmaceutical
Main Luck Pharmaceuticals
Sanjiu Medical
Livzon Pharmaceutical
Segment by Type
Radiotherapy
Chemotherapy
Immunotherapy
Hormone therapy
Targeted therapy
Segment by Application
Cancer Research Institutes
Cancer Hospitals
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oncology Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oncology Adjuvants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Oncology Adjuvants Market Overview
1.1 Product Overview and Scope of Oncology Adjuvants
1.2 Oncology Adjuvants Segment by Type
1.2.1 Global Oncology Adjuvants Market Value Comparison by Type (2024-2030)
1.2.2 Radiotherapy
1.2.3 Chemotherapy
1.2.4 Immunotherapy
1.2.5 Hormone therapy
1.2.6 Targeted therapy
1.3 Oncology Adjuvants Segment by Application
1.3.1 Global Oncology Adjuvants Market Value by Application: (2024-2030)
1.3.2 Cancer Research Institutes
1.3.3 Cancer Hospitals
1.4 Global Oncology Adjuvants Market Size Estimates and Forecasts
1.4.1 Global Oncology Adjuvants Revenue 2019-2030
1.4.2 Global Oncology Adjuvants Sales 2019-2030
1.4.3 Global Oncology Adjuvants Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oncology Adjuvants Market Competition by Manufacturers
2.1 Global Oncology Adjuvants Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oncology Adjuvants Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oncology Adjuvants Average Price by Manufacturers (2019-2024)
2.4 Global Oncology Adjuvants Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oncology Adjuvants, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oncology Adjuvants, Product Type & Application
2.7 Oncology Adjuvants Market Competitive Situation and Trends
2.7.1 Oncology Adjuvants Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oncology Adjuvants Players Market Share by Revenue
2.7.3 Global Oncology Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oncology Adjuvants Retrospective Market Scenario by Region
3.1 Global Oncology Adjuvants Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oncology Adjuvants Global Oncology Adjuvants Sales by Region: 2019-2030
3.2.1 Global Oncology Adjuvants Sales by Region: 2019-2024
3.2.2 Global Oncology Adjuvants Sales by Region: 2025-2030
3.3 Global Oncology Adjuvants Global Oncology Adjuvants Revenue by Region: 2019-2030
3.3.1 Global Oncology Adjuvants Revenue by Region: 2019-2024
3.3.2 Global Oncology Adjuvants Revenue by Region: 2025-2030
3.4 North America Oncology Adjuvants Market Facts & Figures by Country
3.4.1 North America Oncology Adjuvants Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oncology Adjuvants Sales by Country (2019-2030)
3.4.3 North America Oncology Adjuvants Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oncology Adjuvants Market Facts & Figures by Country
3.5.1 Europe Oncology Adjuvants Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oncology Adjuvants Sales by Country (2019-2030)
3.5.3 Europe Oncology Adjuvants Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oncology Adjuvants Market Facts & Figures by Country
3.6.1 Asia Pacific Oncology Adjuvants Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oncology Adjuvants Sales by Country (2019-2030)
3.6.3 Asia Pacific Oncology Adjuvants Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Oncology Adjuvants Market Facts & Figures by Country
3.7.1 Latin America Oncology Adjuvants Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oncology Adjuvants Sales by Country (2019-2030)
3.7.3 Latin America Oncology Adjuvants Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oncology Adjuvants Market Facts & Figures by Country
3.8.1 Middle East and Africa Oncology Adjuvants Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oncology Adjuvants Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oncology Adjuvants Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oncology Adjuvants Sales by Type (2019-2030)
4.1.1 Global Oncology Adjuvants Sales by Type (2019-2024)
4.1.2 Global Oncology Adjuvants Sales by Type (2025-2030)
4.1.3 Global Oncology Adjuvants Sales Market Share by Type (2019-2030)
4.2 Global Oncology Adjuvants Revenue by Type (2019-2030)
4.2.1 Global Oncology Adjuvants Revenue by Type (2019-2024)
4.2.2 Global Oncology Adjuvants Revenue by Type (2025-2030)
4.2.3 Global Oncology Adjuvants Revenue Market Share by Type (2019-2030)
4.3 Global Oncology Adjuvants Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oncology Adjuvants Sales by Application (2019-2030)
5.1.1 Global Oncology Adjuvants Sales by Application (2019-2024)
5.1.2 Global Oncology Adjuvants Sales by Application (2025-2030)
5.1.3 Global Oncology Adjuvants Sales Market Share by Application (2019-2030)
5.2 Global Oncology Adjuvants Revenue by Application (2019-2030)
5.2.1 Global Oncology Adjuvants Revenue by Application (2019-2024)
5.2.2 Global Oncology Adjuvants Revenue by Application (2025-2030)
5.2.3 Global Oncology Adjuvants Revenue Market Share by Application (2019-2030)
5.3 Global Oncology Adjuvants Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Eli Lilly Oncology Adjuvants Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Oncology Adjuvants Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 BMS
6.3.1 BMS Corporation Information
6.3.2 BMS Description and Business Overview
6.3.3 BMS Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.3.4 BMS Oncology Adjuvants Product Portfolio
6.3.5 BMS Recent Developments/Updates
6.4 Biogen
6.4.1 Biogen Corporation Information
6.4.2 Biogen Description and Business Overview
6.4.3 Biogen Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biogen Oncology Adjuvants Product Portfolio
6.4.5 Biogen Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sanofi Oncology Adjuvants Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.6.4 AstraZeneca Oncology Adjuvants Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Oncology Adjuvants Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Hengrui Medicine
6.8.1 Hengrui Medicine Corporation Information
6.8.2 Hengrui Medicine Description and Business Overview
6.8.3 Hengrui Medicine Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hengrui Medicine Oncology Adjuvants Product Portfolio
6.8.5 Hengrui Medicine Recent Developments/Updates
6.9 Hisun Pharmaceutical
6.9.1 Hisun Pharmaceutical Corporation Information
6.9.2 Hisun Pharmaceutical Description and Business Overview
6.9.3 Hisun Pharmaceutical Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Hisun Pharmaceutical Oncology Adjuvants Product Portfolio
6.9.5 Hisun Pharmaceutical Recent Developments/Updates
6.10 Yibai Pharmaceutical
6.10.1 Yibai Pharmaceutical Corporation Information
6.10.2 Yibai Pharmaceutical Description and Business Overview
6.10.3 Yibai Pharmaceutical Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Yibai Pharmaceutical Oncology Adjuvants Product Portfolio
6.10.5 Yibai Pharmaceutical Recent Developments/Updates
6.11 SL Pharmaceutical
6.11.1 SL Pharmaceutical Corporation Information
6.11.2 SL Pharmaceutical Oncology Adjuvants Description and Business Overview
6.11.3 SL Pharmaceutical Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.11.4 SL Pharmaceutical Oncology Adjuvants Product Portfolio
6.11.5 SL Pharmaceutical Recent Developments/Updates
6.12 Zhendong Pharmaceutical
6.12.1 Zhendong Pharmaceutical Corporation Information
6.12.2 Zhendong Pharmaceutical Oncology Adjuvants Description and Business Overview
6.12.3 Zhendong Pharmaceutical Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Zhendong Pharmaceutical Oncology Adjuvants Product Portfolio
6.12.5 Zhendong Pharmaceutical Recent Developments/Updates
6.13 Main Luck Pharmaceuticals
6.13.1 Main Luck Pharmaceuticals Corporation Information
6.13.2 Main Luck Pharmaceuticals Oncology Adjuvants Description and Business Overview
6.13.3 Main Luck Pharmaceuticals Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Main Luck Pharmaceuticals Oncology Adjuvants Product Portfolio
6.13.5 Main Luck Pharmaceuticals Recent Developments/Updates
6.14 Sanjiu Medical
6.14.1 Sanjiu Medical Corporation Information
6.14.2 Sanjiu Medical Oncology Adjuvants Description and Business Overview
6.14.3 Sanjiu Medical Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Sanjiu Medical Oncology Adjuvants Product Portfolio
6.14.5 Sanjiu Medical Recent Developments/Updates
6.15 Livzon Pharmaceutical
6.15.1 Livzon Pharmaceutical Corporation Information
6.15.2 Livzon Pharmaceutical Oncology Adjuvants Description and Business Overview
6.15.3 Livzon Pharmaceutical Oncology Adjuvants Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Livzon Pharmaceutical Oncology Adjuvants Product Portfolio
6.15.5 Livzon Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oncology Adjuvants Industry Chain Analysis
7.2 Oncology Adjuvants Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oncology Adjuvants Production Mode & Process
7.4 Oncology Adjuvants Sales and Marketing
7.4.1 Oncology Adjuvants Sales Channels
7.4.2 Oncology Adjuvants Distributors
7.5 Oncology Adjuvants Customers
8 Oncology Adjuvants Market Dynamics
8.1 Oncology Adjuvants Industry Trends
8.2 Oncology Adjuvants Market Drivers
8.3 Oncology Adjuvants Market Challenges
8.4 Oncology Adjuvants Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
